Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) is 62.14% higher on its value in year-to-date trading and has touched a low of $32.56 and a high of $62.53 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CRNX stock was last observed hovering at around $57.11 in the last trading session, with the day’s gains setting it 0.58%.
Currently trading at $57.69, the stock is 0.58% and 2.76% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.81 million and changing 1.02% at the moment leaves the stock 15.87% off its SMA200. CRNX registered 72.21% gain for a year compared to 6-month gain of 25.85%. The firm has a 50-day simple moving average (SMA 50) of $55.9968 and a 200-day simple moving average (SMA200) of $49.6812.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -0.21% loss in the last 1 month and extending the period to 3 months gives it a 14.49%, and is 0.03% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.15% over the week and 3.99% over the month.
Crinetics Pharmaceuticals Inc (CRNX) has around 290 employees, a market worth around $5.35B and $0.00M in sales. Distance from 52-week low is 77.21% and -7.74% from its 52-week high. The company has generated returns on investments over the last 12 months (-31.65%).
The EPS is expected to shrink by -0.20% this year
340.0 institutions hold shares in Crinetics Pharmaceuticals Inc (CRNX), with institutional investors hold 96.44% of the company’s shares. The shares outstanding are 92.74M, and float is at 86.70M with Short Float at 7.50%. Institutions hold 94.71% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 6.23 million shares valued at $279.06 million. The investor’s holdings represent 8.6187 of the CRNX Shares outstanding. As of 2024-06-30, the second largest holder is DRIEHAUS CAPITAL MANAGEMENT LLC with 6.11 million shares valued at $273.76 million to account for 8.4552 of the shares outstanding. The other top investors are WELLINGTON MANAGEMENT GROUP LLP which holds 4.62 million shares representing 6.3916 and valued at over $206.95 million, while VANGUARD GROUP INC holds 6.245 of the shares totaling 4.51 million with a market value of $202.2 million.
Crinetics Pharmaceuticals Inc (CRNX) Insider Activity
The most recent transaction is an insider sale by Struthers Richard Scott, the company’s President & CEO. SEC filings show that Struthers Richard Scott sold 10,000 shares of the company’s common stock on Dec 02 ’24 at a price of $57.57 per share for a total of $0.58 million. Following the sale, the insider now owns 100000.0 shares.
Still, SEC filings show that on Nov 22 ’24, Knight Jeff E. (Chief Operating Officer) disposed off 501 shares at an average price of $56.52 for $28317.0. The insider now directly holds 51,653 shares of Crinetics Pharmaceuticals Inc (CRNX).
